Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Glycopyrrolate and formoterol fumarate

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Glycopyrrolate and formoterol fumarate key facts

Used for
BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). (source)
Prescription or over the counter
Prescription (Rx)
Generic available
No generic listed by the FDA
Typical pharmacy cost
$40.86 per gram (formoterol fumarate 4.8 ug · glycopyrrolate 9 ug; NADAC)
Latest FDA recall
March 15, 2021 (Class II)

Sources: FDA label (March 24, 2023); FDA NDC Directory (November 13, 2026); CMS NADAC (November 11, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Glycopyrrolate and formoterol fumarate used for?
The FDA-approved label (Bevespi Aerosphere, AstraZeneca Pharmaceuticals LP, March 24, 2023) says: “BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BEVESPI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma […]. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Glycopyrrolate and formoterol fumarate?
The “Adverse Reactions” section of the FDA label (Bevespi Aerosphere, AstraZeneca Pharmaceuticals LP, March 24, 2023) begins: “The following adverse reactions are described in greater detail elsewhere in the labeling: • Paradoxical bronchospasm [see Warnings and Precautions (5.4)] • Hypersensitivity reactions including Anaphylaxis [see Contraindications (4), Warnings and Precautions (5.5)] • Cardiovascular effects [see Warnings and Precautions (5.6)] • Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.7)] • Worsening of urinary retention [see Warnings and Precautions (5.8)] Most common adverse reactions (incidence ≥2% and more common than with placebo) include: urinary tract infection and cough.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Glycopyrrolate and formoterol fumarate?
The “Drug Interactions” section of the FDA label (Bevespi Aerosphere, AstraZeneca Pharmaceuticals LP, March 24, 2023) begins: “No formal drug interaction studies have been performed with BEVESPI AEROSPHERE. • Other adrenergic drugs may potentiate effect: Use with caution (5.3, 7.1) • Xanthine derivatives, steroids, diuretics or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. Use with caution. (7.2, 7.3) • Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with non-potassium sparing diuretics may worsen with concomitant beta 2 -agonists.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Glycopyrrolate and formoterol fumarate have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Glycopyrrolate and formoterol fumarate?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Glycopyrrolate and formoterol fumarate been recalled?
FDA enforcement reports list 1 recall of products of this medicine; the newest started March 15, 2021 (Class II). A recall usually concerns specific lots, not every product.
Who makes Glycopyrrolate and formoterol fumarate?
1 company lists prescription products of Glycopyrrolate and formoterol fumarate in the FDA NDC Directory, including AstraZeneca Pharmaceuticals LP.

What Glycopyrrolate and formoterol fumarate is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BEVESPI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma […]. …

— FDA label: Bevespi Aerosphere, AstraZeneca Pharmaceuticals LP, effective March 24, 2023. Read the full label on DailyMed →

Label quoted: the one for the most common form (aerosol, metered, respiratory (inhalation)), Bevespi Aerosphere, AstraZeneca Pharmaceuticals LP; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Glycopyrrolate and formoterol fumarate side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The following adverse reactions are described in greater detail elsewhere in the labeling:

  • Paradoxical bronchospasm [see Warnings and Precautions (5.4)]
  • Hypersensitivity reactions including Anaphylaxis [see Contraindications (4), Warnings and Precautions (5.5)]
  • Cardiovascular effects [see Warnings and Precautions (5.6)]
  • Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.7)]
  • Worsening of urinary retention [see Warnings and Precautions (5.8)] Most common adverse reactions (incidence ≥2% and more common than with placebo) include: urinary tract infection and cough.
Read more of this section

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. The clinical program for BEVESPI AEROSPHERE included 4,911 subjects with COPD in two 24-week lung function trials, one long-term safety extension study of 28 weeks, and 10 other trials of shorter duration. A total of 1,302 subjects have received at least 1 dose of BEVESPI AEROSPHERE. The safety data described below are based on the two 24-week trials and the one 28-week long-term safety extension trial. Adverse reactions observed in the other trials were similar to those observed in these confirmatory trials. 24-Week Trials The incidence of adverse reactions with BEVESPI AEROSPHERE in Table 1 is based on reports in two 24-week, placebo-controlled trials (Trials 1 and 2; n=2,100 and n=1,610, respectively). Of the 3,710 subjects, 56% were male and 91% were Caucasian. They had a mean age of 63 years and an average smoking history of 51 pack-years, with 54% identified as current smokers. At screening, the mean post-bronchodilator percent predicted forced expiratory volume in 1 second (FEV 1) was 51% (range: 19% to 82%) and the mean percent reversibility was 20% (range: -32% to 135%). Subjects received one of the following treatments: BEVESPI AEROSPHERE, glycopyrrolate 18 mcg, formoterol fumarate 9.6 mcg, or placebo twice daily or active control. Table 1 - Adverse Reactions with BEVESPI AEROSPHERE ≥2% Incidence and More Common than with Placebo in Subjects with Chronic Obstructive Pulmonary Disease Adverse Reaction BEVESPI AEROSPHERE (n=1036) % Glycopyrrolate 18 mcg BID (n=890) % Formoterol Fumarate 9.6 mcg BID (n=890) % Placebo (n=443) % Respiratory, thoracic, and mediastinal disorders Cough 4.0 3.0 2.7 2.7 Infections and infestation Urinary tract infection 2.6 1.8 1.5 2.3 Other adverse reactions defined as events with an incidence of >1% but less than 2% with BEVESPI AEROSPHERE but more common than with placebo included the following: arthralgia, chest pain, tooth abscess, muscle spasms, headache, oropharyngeal pain, vomiting, pain in extremity, dizziness, anxiety, dry mouth, fall, influenza, fatigue, acute sinusitis, and contusion.

— FDA label: Bevespi Aerosphere, AstraZeneca Pharmaceuticals LP, effective March 24, 2023. This is part of the section. Read the full label on DailyMed →

Glycopyrrolate and formoterol fumarate drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

No formal drug interaction studies have been performed with BEVESPI AEROSPHERE.

  • Other adrenergic drugs may potentiate effect: Use with caution (5.3, 7.1)
  • Xanthine derivatives, steroids, diuretics or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. Use with caution. (7.2, 7.3)
  • Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with non-potassium sparing diuretics may worsen with concomitant beta 2 -agonists.
Read more of this section

(7.3)

  • Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of formoterol fumarate on cardiovascular system. (7.4)
  • Beta-blockers: Use with caution and only when medically necessary. (7.5)
  • Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administrations of BEVESPI AEROSPHERE with other anticholinergic-containing drugs. (7.6) 7.1 Adrenergic Drugs If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of formoterol, a component of BEVESPI AEROSPHERE, may be potentiated [see Warnings and Precautions (5.3)]. 7.2 Xanthine Derivatives, Steroids, or Diuretics Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of beta 2 adrenergic agonists such as formoterol, a component of BEVESPI AEROSPHERE. 7.3 Non-Potassium Sparing Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta 2 -agonists, especially when the recommended dose of the beta 2 -agonist is exceeded. Approximately 17% of subjects were taking non-potassium sparing diuretics during the two 24-week placebo-controlled trials in subjects with COPD. The incidence of adverse events in subjects taking non-potassium-sparing diuretics was similar between BEVESPI AEROSPHERE and placebo treatment groups. In addition, there was no evidence of a treatment effect on serum potassium with BEVESPI AEROSPHERE compared to placebo in subjects taking non-potassium sparing diuretics during the two 24-week trials. However, caution is advised in the coadministration of BEVESPI AEROSPHERE with non-potassium-sparing diuretics. 7.4 Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, QTc Prolonging Drugs BEVESPI AEROSPHERE, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants or other drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents. Drugs that are known to prolong the QTc interval may be associated with an increased risk of ventricular arrhythmias. 7.5 Beta-Blockers Beta-adrenergic receptor antagonists (beta-blockers) and BEVESPI AEROSPHERE may interfere with the effect of each other when administered concurrently. Beta-blockers not only block the therapeutic effects of beta 2 -agonists, but may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers.

— FDA label: Bevespi Aerosphere, AstraZeneca Pharmaceuticals LP, effective March 24, 2023. This is part of the section. Read the full label on DailyMed →

Glycopyrrolate and formoterol fumarate dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

  • For oral inhalation only.
  • Maintenance treatment of COPD: 2 inhalations of BEVESPI AEROSPHERE twice daily by oral inhalation. (2) 2.1 Recommended Dosage and Administration The recommended dosage of BEVESPI AEROSPHERE is glycopyrrolate 18 mcg and formoterol fumarate 9.6 mcg (administered as two inhalations of BEVESPI AEROSPHERE [glycopyrrolate/formoterol fumarate 9 mcg/4.8 mcg]) twice daily in the morning and in the evening by oral inhalation.
Read more of this section

Do not take more than two inhalations twice daily. 2.2 Preparation Prime BEVESPI AEROSPHERE before using for the first time. Priming BEVESPI AEROSPHERE is essential to ensure appropriate drug content in each actuation. To prime BEVESPI AEROSPHERE, release 4 sprays into the air away from the face, shaking well before each spray. BEVESPI AEROSPHERE must be re-primed when the inhaler has not been used for more than 7 days. To re-prime BEVESPI AEROSPHERE, release 2 sprays into the air away from the face, shaking well before each spray. 2.3 Dose Counter The canister has an attached dose indicator, which indicates how many inhalations remain. The dose indicator display will move after every tenth actuation. When nearing the end of the usable inhalations, the color behind the number in the dose indicator display window changes to red. BEVESPI AEROSPHERE should be discarded when the dose indicator display window shows zero.

— FDA label: Bevespi Aerosphere, AstraZeneca Pharmaceuticals LP, effective March 24, 2023. Read the full label on DailyMed →

Glycopyrrolate and formoterol fumarate in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary There are no adequate and well-controlled trials of BEVESPI AEROSPHERE or its individual components, glycopyrrolate and formoterol fumarate, in pregnant women to inform a drug-associated risk.

Read more of this section

In animal reproduction studies, glycopyrrolate alone, administered by the subcutaneous route in rats and rabbits, did not cause structural abnormalities or affect fetal survival at exposures approximately 2700 and 5400 times from the maximum recommended human daily inhalation dose (MRHDID), respectively. Glycopyrrolate had no effects on the physical, functional, and behavioral development of rat pups with exposures up to 2700 times the MRHDID. Formoterol fumarate alone, administered by the oral route in rats and rabbits, caused structural abnormalities at 1500 and 61,000 times the MRHDID, respectively. Formoterol fumarate was also embryocidal, increased pup loss at birth and during lactation, and decreased pup weight in rats at 110 times the MRHDID. These adverse effects generally occurred at large multiples of the MRHDID when formoterol fumarate was administered by the oral route to achieve high systemic exposures. No structural abnormalities, embryocidal, or developmental effects were seen in rats that received inhalation doses up to 350 times the MRHDID. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Labor or Delivery: There are no well-controlled human trials that have investigated the effects of BEVESPI AEROSPHERE on preterm labor or labor at term. Because beta 2 -agonists may potentially interfere with uterine contractility, BEVESPI AEROSPHERE should be used during labor only if the potential benefit justifies the potential risk. Data Animal Data Glycopyrrolate In an embryo-fetal development study in pregnant rats dosed during the period of organogenesis from gestation days 6 to 17, glycopyrrolate produced no structural abnormalities or effects on fetal survival; however, slight reductions of fetal body weight in the presence of maternal toxicity at the highest tested dose that was 2700 times the MRHDID (on a mcg/m 2 basis at a maternal subcutaneous dose of 10,000 mcg/kg/day). Fetal body weights were unaffected with doses up to 270 times the MRHDID (on a mcg/m 2 basis with maternal subcutaneous doses up to 1000 mcg/kg/day). Maternal toxicity was observed with doses 270 times the MRHDID and higher (on a mcg/m 2 basis with maternal subcutaneous doses of 1000 mcg/kg/day and higher).

— FDA label: Bevespi Aerosphere, AstraZeneca Pharmaceuticals LP, effective March 24, 2023. This is part of the section. Read the full label on DailyMed →

When Glycopyrrolate and formoterol fumarate should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

BEVESPI AEROSPHERE is contraindicated in:

  • use of a long-acting beta 2 -adrenergic agonist (LABA), including formoterol fumarate, one of the active ingredients in BEVESPI AEROSPHERE, without an inhaled corticosteroid, in patients with asthma [see Warnings and Precautions (5.1)]. BEVESPI AEROSPHERE is not indicated for the treatment of asthma.
Read more of this section
  • patients with hypersensitivity to glycopyrrolate, formoterol fumarate, or to any component of the product [see Warnings and Precautions (5.5)].
  • Use of a LABA, including formoterol fumarate, one of the active ingredients in BEVESPI AEROSPHERE, without an inhaled corticosteroid is contraindicated in patients with asthma. (4)
  • Hypersensitivity to glycopyrrolate, formoterol fumarate, or to any component of this product. (4, 5.5)

— FDA label: Bevespi Aerosphere, AstraZeneca Pharmaceuticals LP, effective March 24, 2023. Read the full label on DailyMed →

Glycopyrrolate and formoterol fumarate overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

No cases of overdose have been reported with BEVESPI AEROSPHERE. BEVESPI AEROSPHERE contains both glycopyrrolate and formoterol fumarate; therefore, the risks associated with overdosage for the individual components described below apply to BEVESPI AEROSPHERE. Treatment of overdosage consists of discontinuation of BEVESPI AEROSPHERE together with institution of appropriate symptomatic and/or supportive therapy.

Read more of this section

The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. Cardiac monitoring is recommended in case of overdosage. Glycopyrrolate High doses of glycopyrrolate, a component of BEVESPI AEROSPHERE, may lead to anticholinergic signs and symptoms such as nausea, vomiting, dizziness, lightheadedness, blurred vision, increased intraocular pressure (causing pain, vision disturbances or reddening of the eye), obstipation or difficulties in voiding. Formoterol Fumarate An overdose of formoterol fumarate would likely lead to an exaggeration of effects that are typical for beta 2 -agonists: seizures, angina, hypertension, hypotension, tachycardia, atrial and ventricular tachyarrhythmias, nervousness, headache, tremor, palpitations, muscle cramps, nausea, dizziness, sleep disturbances, metabolic acidosis, hyperglycemia, hypokalemia. As with all sympathomimetic medications, cardiac arrest and even death may be associated with overdosage of formoterol fumarate.

— FDA label: Bevespi Aerosphere, AstraZeneca Pharmaceuticals LP, effective March 24, 2023. Read the full label on DailyMed →

Forms and how it is given

Dosage formsAerosol, metered
RouteRespiratory (inhalation)
Prescription products1 in the FDA NDC Directory
Brand namesBevespi Aerosphere

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Glycopyrrolate and formoterol fumarate, by strength and form
Strength and formGeneric or brandPharmacies pay
formoterol fumarate 4.8 ug · glycopyrrolate 9 ug
aerosol, metered
Brand: Bevespi Aerosphere $40.86 per gram

NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA208294
BEVESPI AEROSPHERE
AstrazenecaApril 25, 2016 2, latest November 5, 2020
2020: Labeling · 2019: Labeling

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.

  1. March 15, 2021 · Class II · Terminated · D-0434-2021

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

    Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) Inhalation Aerosol 9 mcg/4.8 mcg per inhalation For Oral Inhalation only 120 inhalations Rx Only NDC 0310-4600-12 Mfd for: AstraZeneca Pharmaceuticals, LP, Wilm — Cardinal Health Inc.

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Official identifiers

RxCUI (RxNorm)1790639, 1790644
SPL set ID of the quoted labelae02436e-9528-490e-a844-0c0f6f2843f9
FDA labels (SPL)1
FDA applicationsNDA208294
Active ingredients (FDA)FORMOTEROL FUMARATE / GLYCOPYRROLATE

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Bevespi Aerosphere, AstraZeneca Pharmaceuticals LP, effective March 24, 2023; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers